Total drug costs grew to $2 billion in 2021, rising steadily from $1.4 billion in 2017, according to Green Shield Canada’s annual drug trends report. The report, which is based on claims reported by Green Shield Canada, found the number of claimants also increased from 1.9 million to 2.1 million over the same period. While […]
Canadian life and health insurers processed nearly $600 million in claims related to mental health in 2021, up 45 per cent since 2020 and 75 per cent since 2019, according to the Canadian Life and Health Insurance Association’s annual fact book. “2021 was a year of recovery and insurers have been proud partners helping employers […]
Average benefits costs for U.S. employers will increase 6.5 per cent — or more than $13,800 per employee — in 2023, according to a new report by Aon. This projection is more than double the three per cent increase to health-care budgets from 2021 to 2022, but below the 9.1 inflation figure reported through the consumer price […]
The amendments to the Patented Medicine Prices Review Board regulations are officially taking effect July 1, after being delayed multiple times. The changes, which were originally proposed in 2019, are the first significant update to the regulations in more than 30 years. After consulting with stakeholders, Health Canada will be moving forward with the implementation of […]
As the coronavirus pandemic continues, fewer Canadian benefits plan members are making drug claims, according to Telus Health’s annual drug trends report. The report, based on the drug claims activity of more than 10 million plan members in 2021, found just 56 per cent made a claim in 2021, reflecting a decreased frequency of in-person […]
While medications used for treating inflammatory disease accounted for just 0.7 per cent of claims across Telus Health’s Canadian block of business in 2021, they represent the largest percentage of eligible drug costs at 12.6 per cent, due to the prevalence of high-cost treatments in this drug class. By comparison, diabetes medications accounted for 12 […]
A British Columbia labour arbitration decision is providing insight on how a block level implementation of a benefits provider’s drug cost-control program violated a collective agreement in a unionized workplace. The Douglas College Faculty Association grieved the implementation of Manulife’s DrugWatch program contravened their collective agreement, which ensured “there will be no change to the […]
After multiple delays, the amendments to the Patented Medicines Review Board regulations will finally come into force on July 1, 2022. Last week, Health Minister Jean-Yves Duclos announced the federal government will proceed with the amendments to provide the PMPRB with new tools to protect Canadians from excessive prices for patented medicines. “This will improve access for […]
This month marks the second anniversary of the beginning of the coronavirus pandemic, a 24-month span that has had profound effects on the health of benefits plan members and the status and structure of their plans. For drug plans in particular, several trends have come to light — or have accelerated — during the course […]
Federal Health Minister Jean-Yves Duclos has put a six-month pause on new regulations designed to lower the cost of patented medicines in Canada. Health Canada first announced in 2019 that the Patented Medicine Prices Review Board would change how it sets a price cap on medicines in Canada in an effort to lower excessively expensive […]